Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
| Autor: | Raoul Tibes, John Mascarenhas, Craig B. Reeder, Jeanne Palmer, Krisstina L. Gowin, Ruben A. Mesa, Katherine Gano, Heidi E. Kosiorek, John K. Camoriano, Amylou C. Dueck, Ronald Hoffman |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Ruxolitinib Combination therapy Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Nitriles medicine Humans Myelofibrosis Myeloproliferative neoplasm Aged Danazol business.industry Anemia Hematology Middle Aged medicine.disease Thrombocytopenia Hematologic Response Surgery Pyrimidines Treatment Outcome Oncology Tolerability Primary Myelofibrosis 030220 oncology & carcinogenesis Pyrazoles Drug Therapy Combination Female business Progressive disease 030215 immunology medicine.drug |
| Zdroj: | Leukemia Research. 60:31-35 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2017.06.005 |
| Popis: | Myelofibrosis is a myeloproliferative neoplasm that is characterized by splenomegaly, profound symptom burden, and cytopenias. JAK inhibitor therapy offers improvements in splenomegaly, symptom burden, and potentially survival; however, cytopenias remain a significant challenge. Danazol has previously demonstrated improvements in myelofibrosis-associated anemia. We conducted a phase II clinical trial evaluating the efficacy and tolerability of combination therapy with ruxolitinib, an oral JAK inhibitor, and danazol. Fourteen intermediate or high-risk MF patients were enrolled at 2 institutions. Responses per IWG-MRT criteria were stable disease in 9 patients (64.2%) clinical improvement in 3 (21.4%) all of which were spleen responses, partial response in 1 (7.1%) and progressive disease in 1 (7.1%). Despite limited IWG-MRT response, stabilization of anemia and thrombocytopenia was demonstrated. In JAK inhibitor naïve patients, 4/5 (80%) had stable or increasing hemoglobin. Of the 9 patients on prior JAK inhibitor, 5 patients (55.5%) and 8 patients (88.9%) had stable or increasing hemoglobin or platelet levels, respectively. Adverse events possibly related included grade 3 or greater hematologic toxicity in ten patients (71.4%) and non-hematologic toxicity in two patients (14.3%). Although combination therapy did not lead to increased hematologic response per IWG-MRT criteria, hematologic stabilization was observed and may be clinically useful. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect